US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...
The American Journal of Managed Care1h
Inebilizumab FDA Approved as First Treatment for IgG4-RD
Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...
US Senate confirms Trump's Medicare and Medicaid nominee Mehmet Oz
A majority of U.S. Senators voted on Thursday to confirm Dr. Mehmet Oz, the celebrity physician nominated by President Donald ...
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...
Explore more
Amgen gets expanded FDA label approval for Uplizna
Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...
Judge throws out lawsuit challenging Colorado’s ability to cap prices on prescription drugs
A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...
Amgen stock rises following FDA approval of UPLIZNA
The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ ...